Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 29/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

85.7%

-0.9% vs benchmark

Late-Stage Pipeline

43%

9 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results86% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (4)
P 2 (1)
P 3 (3)
P 4 (6)

Trial Status

Completed12
Unknown3
Recruiting2
Terminated2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

85.7%

Benchmark: 86.6%

Based on 12 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07748143CompletedPrimary

To Evaluate the Impact of MRSA Nasal Screen Implementation.

NCT04297592Phase 4Enrolling By Invitation

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT04793152Not ApplicableRecruitingPrimary

Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC

NCT05696132Phase 2TerminatedPrimary

Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients

NCT04104178Phase 3CompletedPrimary

Optimal Treatment of MRSA Throat Carriers

NCT05268120Not ApplicableRecruitingPrimary

MRSA Decolonization in Complicated Carriage

NCT02127658Phase 4TerminatedPrimary

MRSA Eradication and Decolonization in Children

NCT05395520UnknownPrimary

Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?

NCT03181932Phase 3CompletedPrimary

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT02547116Phase 4Withdrawn

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

NCT02690415CompletedPrimary

Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses

NCT03304873Phase 3CompletedPrimary

Retapamulin as a Decolonizing Agent for MRSA

NCT04312776CompletedPrimary

Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS

NCT03601741Not ApplicableCompletedPrimary

Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination

NCT04083092UnknownPrimary

Surveillance of Community-Associated MRSA

NCT01318213CompletedPrimary

Benefits of Universal Glove and Gowning

NCT03268122Not ApplicableCompletedPrimary

Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE

NCT02029872Phase 4CompletedPrimary

Stop Community MRSA Colonization Among Patients

NCT01167452Phase 4Completed

Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

NCT02443064Phase 4Unknown

Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin

Scroll to load more

Research Network

Activity Timeline